Slingshot Insights

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

BLCM

100%

Additional Information

Management Comment "BPX-401 our CIDeCAR therapy constructed with Bellicum’s novel proprietary dual co-stimulatory domain MC again MyD88/CD40 and in this case the CaspaCIDe safety switch is on track to enter the clinic in the second half of 2016 for the treatment of CD19 expressing cancers. Bellicum presented a palliative preclinical data at ASH 2015 highlighting BPX-401’s potent anti-tumor effects showing that MC co-stimulation increased T cell proliferation at enhanced efficacy in lymphoma and solid tumor models in vivo compared to CAR-T cell that included the more commonly utilized co-stimulatory molecule CD28. The CD19 target at BPX-401 CAR-T therapy was also able to rapidly normalize a dose dependent elevation of cytokines, analogous to cytokine release syndrome upon administration of rimiducid without loss of tumor control."
-CEO Tom Farrell

http://seekingalpha....

Additional Relevant Details In July 2016, the Company decided to support CD19 programs designed to establish clinical proof-of-concept for CaspaCIDe in the CD19 setting being advanced by two of our academic collaborators, in place of advancing BPX-401.

http://ir.bellicum.c...

Catalyst

Do you think this event is important to the companies below? How will it affect their stock price?

Additional Information

Slingshot Insights Explained